Elicio Therapeutics宣布Eli-002 7P在正在进行的2期Amplify-7P试验中,99%的可评估患者产生了强劲的Mkras特异性T细胞反应
Elicio Therapeutics宣布Eli-002 7P在正在进行的2期Amplify-7P试验中,99%的可评估患者产生了强劲的Mkras特异性T细胞反应
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.